BIO.B vs. BIO, RVTY, TXG, OLK, AVTR, ILMN, WAT, ASND, PEN, and CERE
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Bio-Rad Laboratories (BIO), Revvity (RVTY), 10x Genomics (TXG), Olink Holding AB (publ) (OLK), Avantor (AVTR), Illumina (ILMN), Waters (WAT), Ascendis Pharma A/S (ASND), Penumbra (PEN), and Cerevel Therapeutics (CERE). These companies are all part of the "medical" sector.
Bio-Rad Laboratories (NYSE:BIO.B) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends.
In the previous week, Bio-Rad Laboratories had 7 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 8 mentions for Bio-Rad Laboratories and 1 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.54 beat Bio-Rad Laboratories' score of 0.00 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.
Bio-Rad Laboratories received 237 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. Likewise, 64.87% of users gave Bio-Rad Laboratories an outperform vote while only 57.60% of users gave Bio-Rad Laboratories an outperform vote.
Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.
Bio-Rad Laboratories has a consensus target price of $461.00, suggesting a potential upside of 56.88%. Given Bio-Rad Laboratories' higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Rad Laboratories.
0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 17.1% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Bio-Rad Laboratories has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
Summary
Bio-Rad Laboratories beats Bio-Rad Laboratories on 9 of the 11 factors compared between the two stocks.
Get Bio-Rad Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BIO.B vs. The Competition
Bio-Rad Laboratories Competitors List
Related Companies and Tools
